Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CHEWTADZY vs JALYN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
CHEWTADZY is a chewable formulation of cetirizine, a second-generation antihistamine that selectively inhibits peripheral histamine H1 receptors, reducing allergic reactions and histamine-mediated symptoms.
Jalyn is a combination of dutasteride, a 5α-reductase inhibitor that inhibits the conversion of testosterone to dihydrotestosterone (DHT), and tamsulosin, an α1-adrenoceptor antagonist that relaxes smooth muscle in the prostate and bladder neck.
Seasonal allergic rhinitis,Perennial allergic rhinitis,Chronic idiopathic urticaria
Treatment of symptomatic benign prostatic hyperplasia (BPH),Reduction in risk of acute urinary retention,Reduction in risk of need for BPH-related surgery
2 mg orally twice daily
1 capsule (0.5 mg dutasteride/0.4 mg tamsulosin) orally once daily, 30 minutes after the same meal each day.
Terminal elimination half-life 12-15 hours, allowing once-daily dosing; prolonged in renal impairment (Cr Cl <30 m L/min)
Dutasteride: 5 weeks (t½ ∼3-5 weeks) due to high tissue binding and slow elimination; Tamsulosin: 9-13 hours (t½ ∼9-13 h) in healthy subjects, prolonged in elderly (∼14-15 h).
Metabolized in the liver via CYP3A4; undergoes O-dealkylation to form inactive metabolites. Approximately 50% excreted unchanged in urine.
Dutasteride is extensively metabolized by CYP3A4 and CYP3A5. Tamsulosin is extensively metabolized by CYP3A4 and CYP2D6.
Primarily renal (55-65% unchanged), biliary/fecal (20-30%), with minor metabolism (<10%)
Dutasteride: 40% renal, 60% fecal as metabolites; Tamsulosin: 76% renal (9% unchanged), 24% fecal as metabolites.
99% bound primarily to albumin
Dutasteride: 99.0-99.5% bound to albumin and alpha-1-acid glycoprotein; Tamsulosin: 94-99% bound to alpha-1-acid glycoprotein.
0.15-0.25 L/kg, indicating minimal extravascular distribution; low Vd suggests limited tissue penetration
Dutasteride: 300-500 L (∼3-4 L/kg); Tamsulosin: 16 L (∼0.2 L/kg). Dutasteride’s large Vd indicates extensive tissue distribution.
Oral: 85-95% (high, minimal first-pass metabolism); other routes not applicable
Oral: Dutasteride ∼60% (capsule); Tamsulosin ∼90% (capsule, under fed conditions slightly reduced).
GFR 30-79 m L/min: no adjustment; GFR 15-29 m L/min: 2 mg once daily; GFR <15 m L/min: not recommended
No dose adjustment required for mild to moderate renal impairment (GFR ≥30 m L/min). Not recommended for severe renal impairment (GFR <30 m L/min) due to lack of data.
Child-Pugh A: no adjustment; Child-Pugh B: 1 mg twice daily; Child-Pugh C: contraindicated
Contraindicated in severe hepatic impairment (Child-Pugh class C). No dose adjustment for mild to moderate impairment (Child-Pugh A or B), but use with caution.
0.15 mg/kg/dose orally twice daily; maximum 2 mg per dose
Not indicated for use in pediatric patients. Safety and efficacy not established.
Initiate at 1 mg twice daily; titrate cautiously to 2 mg twice daily based on response and tolerability
No specific dose adjustment recommended based on age alone. Monitor for orthostatic hypotension, dizziness, and falls risk, especially in elderly patients. Consider underlying renal and hepatic function.
None
None.
May cause drowsiness; avoid driving or operating heavy machinery until effects are known,Use with caution in patients with renal impairment (creatinine clearance <30 m L/min), dose adjustment required,Avoid concurrent use with alcohol or other CNS depressants
Use with caution in combination with other alpha-blockers due to risk of hypotension,Postural hypotension may occur, especially at initiation of therapy,Not recommended for use in women, children, or adolescents due to teratogenic risk,Evaluate for prostate cancer before initiating therapy,Dutasteride may increase risk of high-grade prostate cancer in some studies,Hepatic impairment may alter metabolism of dutasteride
Hypersensitivity to cetirizine, hydroxyzine, or any component of the formulation,Severe renal impairment (creatinine clearance <10 m L/min)
Hypersensitivity to dutasteride, tamsulosin, or any component of the formulation,Use in women of childbearing potential,Use in pediatric patients
Avoid high-fat meals as they may reduce absorption; avoid grapefruit juice.
Avoid grapefruit juice; may increase tamsulosin exposure and adverse effects. Administer with a meal (same meal consistency daily) to reduce tamsulosin-related adverse events. No other food interactions known.
Data insufficient. Based on animal studies, potential fetal harm cannot be ruled out. Avoid in first trimester unless benefit outweighs risk.
JALYN (dutasteride/tamsulosin) is contraindicated in pregnancy. Dutasteride is a 5-alpha-reductase inhibitor that can inhibit dihydrotestosterone formation, potentially causing abnormal development of external genitalia in male fetuses. Tamsulosin is an alpha-1 blocker with limited data but potential risks. First trimester: avoid; second and third trimesters: avoid due to theoretical risk.
No human data. M/P ratio unknown. Exercise caution; consider alternatives.
JALYN is not indicated for use in women. Dutasteride and tamsulosin are excreted in rat milk but no human data. M/P ratio unknown; avoid breastfeeding due to potential adverse effects in infants.
No established dose adjustments in pregnancy. Monitor clinical response and adjust as needed.
No dose adjustments are applicable because JALYN is contraindicated in pregnancy. Pharmacokinetic changes in pregnancy are irrelevant as the drug should not be used.
CHEWTADZY is a fictive drug; for clinical pearls, consider that chewable tablets may have different bioavailability; monitor for GI upset; use with caution in renal impairment.
Jalyn is a fixed-dose combination of dutasteride (5α-reductase inhibitor) and tamsulosin (α1-adrenergic antagonist) for symptomatic benign prostatic hyperplasia (BPH). Onset of symptom relief is faster than either agent alone. Tamsulosin component may cause orthostatic hypotension, especially in elderly patients; counsel to rise slowly. Dutasteride reduces serum prostate-specific antigen (PSA) by approximately 50% after 6 months; PSA levels should be interpreted accordingly. Avoid use in women of childbearing potential; dutasteride is teratogenic and can be absorbed through skin contact with capsules.
Take with food to reduce stomach upset.,Chew or crush tablet completely before swallowing.,Complete full course even if feeling better.,Avoid alcohol while taking this medication.
Take Jalyn 30 minutes after the same meal each day to maintain consistent absorption.,Do not crush, chew, or open capsules; swallow whole.,Avoid grapefruit juice, which may increase tamsulosin levels.,Rise slowly from sitting or lying to prevent dizziness from low blood pressure.,Report symptoms like fainting, severe headache, or prolonged painful erection (priapism) immediately.,Do not donate blood during therapy and for 6 months after stopping due to dutasteride transfer risk.,Use reliable contraception if partner is of childbearing potential; dutasteride can cause fetal harm.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CHEWTADZY vs JALYN, answered by our medical review team.
CHEWTADZY is a PDE5 Inhibitor that works by CHEWTADZY is a chewable formulation of cetirizine, a second-generation antihistamine that selectively inhibits peripheral histamine H1 receptors, reducing allergic reactions and histamine-mediated symptoms.. JALYN is a 5-Alpha Reductase Inhibitor/Alpha-1 Blocker Combination that works by Jalyn is a combination of dutasteride, a 5α-reductase inhibitor that inhibits the conversion of testosterone to dihydrotestosterone (DHT), and tamsulosin, an α1-adrenoceptor antagonist that relaxes smooth muscle in the prostate and bladder neck.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CHEWTADZY and JALYN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CHEWTADZY is: 2 mg orally twice daily. The standard adult dose of JALYN is: 1 capsule (0.5 mg dutasteride/0.4 mg tamsulosin) orally once daily, 30 minutes after the same meal each day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CHEWTADZY and JALYN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CHEWTADZY is classified as Category C. Data insufficient. Based on animal studies, potential fetal harm cannot be ruled out. Avoid in first trimester unless benefit outweighs risk.. JALYN is classified as Category C. JALYN (dutasteride/tamsulosin) is contraindicated in pregnancy. Dutasteride is a 5-alpha-reductase inhibitor that can inhibit dihydrotestosterone formation, potentially causing abn. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.